SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Gilead Sciences

139

Gilead Sciences

GILD

California-based Gilead is a biopharmaceutical firm best known for its hepatitis C cures Sovaldi and Harvoni.

Looking for leads, investment insights, or competitive intelligence?

CEO

Daniel O'Day

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Foster City, Calif.

Years on Fortune 500 List

11

Employees

11,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$22,127-15.2%
Profits ($M)$5,455.017.9%
Assets ($M)$63,675
Total Stockholder Equity ($M)$21,387
Profit Ratios
Profit as % of Revenues24.7%
Profits as % of Assets8.6%
Profits as % of Stockholder Equity25.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)4.17
EPS % Change (from 2017)18.8%
EPS % Change (5 year annual rate)18.2%
EPS % Change (10 year annual rate)14.8%
Total Return
Total Return to Investors (2018)-9.8%
Total Return to Investors (5 year, annualized)-1.7%
Total Return to Investors (10 year, annualized)10.4%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

4 Stocks That Could Soar Under New CEOs

Share prices often plummet when a CEO gets fired, but turnover can be great for investors in the long term.

Read More →
The Best Investing Advice for 2019 From Fortune’s Experts

The economy and the stock market don’t always march in lockstep, and investors got a sharp reminder of that fact this fall. Parade-and-fireworks-worthy GDP growth and employment numbers shared the spotlight with an ugly market slide that took some previously beloved stocks into bear-market territory. Fears about inflation and trade tensions were among the culprits; […]

Read More →
Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion.

Read More →
The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs

Celgene and Novartis are among the companies accused of thwarting generic drugs.

Read More →
Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race

On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.

Read More →